Dessintey

Dessintey operates in the medical-device and neurorehabilitation segment, with a portfolio spanning visual simulation, robotic assistance, implicit learning, interactive therapy, and self-rehabilitation. Its differentiation is less about a single device than about offering a continuum from motor planning to execution and autonomous practice. IVS technologies target action observation, motor imagery, mirror therapy, and pain treatment, while REAplan and hunova extend the portfolio into adaptive robotics, balance assessment, and motor execution. SRT Lab adds group and self-directed therapy, potentially increasing patient activity time beyond one-to-one sessions. The company reports deployment in 30 countries, more than 700 installed devices, and roughly 420,000 sessions annually, indicating established clinical use rather than an early prototype stage. The 2025 acquisition by ARLANE may provide additional capital or operating support, but transaction terms and strategic objectives have not been disclosed.

Dessintey shows a measured growth trajectory from its 2017 founding into a specialized neurorehabilitation platform. A clear inflection point was team expansion from 16 employees in January 2023 to 26 by the end of 2023, representing growth of approximately 63% within the year and spanning R&D, sales, and marketing capabilities. Product breadth also expanded beyond a single rehabilitation device: the portfolio now includes IVS for visual and motor-planning therapy, STIIMP for implicit upper-limb learning, SRT for guided self-rehabilitation, and ARM LAB and GAIT LAB for broader care environments. Website metrics indicate more than 700 devices installed across 30 countries and around 420,000 annual sessions, suggesting that commercialization has progressed alongside product development. The acquisition by ARLANE, announced on Nov 18, 2025, is the latest identifiable strategic inflection point and could support further international distribution, manufacturing, or clinical expansion.